1.95
+0.14(+7.73%)
Currency In USD
| Previous Close | 1.81 |
| Open | 1.82 |
| Day High | 1.95 |
| Day Low | 1.8 |
| 52-Week High | 16.94 |
| 52-Week Low | 1.26 |
| Volume | 65,918 |
| Average Volume | 183,668 |
| Market Cap | 51.01M |
| PE | -0.23 |
| EPS | -8.52 |
| Moving Average 50 Days | 1.69 |
| Moving Average 200 Days | 2.66 |
| Change | 0.14 |
If you invested $1000 in Senti Biosciences, Inc. (SNTI) since IPO date, it would be worth $19.54 as of November 08, 2025 at a share price of $1.95. Whereas If you bought $1000 worth of Senti Biosciences, Inc. (SNTI) shares 3 years ago, it would be worth $89.86 as of November 08, 2025 at a share price of $1.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025
GlobeNewswire Inc.
Nov 03, 2025 2:05 PM GMT
Two presentations, including one oral session, build on existing data and show deep and durable clinical remission rates, combined with a strong safety profile, for SENTI-202 in treating relapsed/refractory Acute Myeloid Leukemia (AML)Pharmacodynamic
Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference
GlobeNewswire Inc.
Oct 16, 2025 1:05 PM GMT
Live webcast presentation on Tuesday, October 21st at 11:35 AM ETSOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation
Senti Bio to Present at BioJapan
GlobeNewswire Inc.
Oct 06, 2025 1:05 PM GMT
In-person presentation on Thursday, October 9th at 11:30 AM JSTSOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation ce